Clinical relevance of apolipoprotein E genotyping based on a family history of Alzheimer’s disease

Current Alzheimer Research

Volumn 12, Issue 3, 2015, Pages 210-217

  Lückhoff, Hilmar K ^a   Brand, Theresa ^a   Van Velden, Dawid P ^a   Kidd, Martin ^a   Fisher, Leslie R ^a   Van Rensburg, Susan J ^a   Kotze, Maritha J ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Alzheimer s disease; Apolipoprotein E; Dyslipidemia; Family history; Genotype phenotype association; Personalized genomics

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FEMALE; GENE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HABIT; HUMAN; LIFESTYLE; MALE; MIDDLE AGED; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK MANAGEMENT; SCREENING; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH AFRICAN; TRIACYLGLYCEROL BLOOD LEVEL; AGED; BODY MASS; FAMILY HEALTH; GENETICS; LONGITUDINAL STUDY; PSYCHOLOGY; RISK FACTOR; SOUTH AFRICA; YOUNG ADULT;

ADULT; AGED; ALZHEIMER DISEASE; APOLIPOPROTEINS E; BODY MASS INDEX; CHOLESTEROL, LDL; FAMILY HEALTH; FEMALE; GENE FREQUENCY; GENOTYPE; HABITS; HUMANS; LIFE STYLE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RISK FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84928988017     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150302154354     Document Type: Article

References (46)

1. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278(16): 1349-1356 (1997).
2. Johnson SC, Schmitz TW, Trivedi MA, Ries ML, Torgerson BM, Carlsson CM, et al. The influence of Alzheimer Disease family history and apolipoprotein E ε4 on mesial temporal lobe activation. J Neurosci 26(22): 6069-6076 (2006).
3. Donix M, Small GW, Bookheimer SY. Family history and APOE-4 genetic risk in Alzheimer's disease. Neuropsychol Rev 22(3): 298-309 (2012).
4. Hashimoto M, Yasuda M, Tanimukai S, Matsui M, Hirono N, Kazui H, et al. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 57(8): 1461-1466 (2001).
5. Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 74(2): 113-120 (2010).
6. Honea RA, Swerdlow RH, Vidoni ED, Burns JM. Progressive regional atrophy in normal adults with a maternal history of Alzheimer disease. Neurology 76(9): 822-829 (2011).
7. Okonkwo OC, Xu G, Dowling NM, Bendlin BB, Larue A, Hermann BP, et al. Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults. Neurology 78(22): 1769-1776 (2012).
8. Bassett SS, Yousem DM, Cristinzio C, Kusevic I, Yassa MA, Caffo BS, et al. Familial risk for Alzheimer’s disease alters fMRI activation patterns. Brain 129(5): 1229-1239 (2006).
9. Trivedi MA, Schmitz TW, Ries ML, Hess TM, Fitzgerald ME, Atwood CS, et al. fMRI activation during episodic encoding and metacognitive appraisal across the lifespan: risk factors for Alzheimer’s disease. Neuropsychologia 46(6): 1667-1678 (2008).
10. Xu G, McLaren DG, Ries ML, Fitzgerald ME, Bendlin BB, Rowley HA, et al. The influence of parental history of Alzheimer’s disease and apolipoprotein E epsilon4 on the BOLD signal during recognition memory. Brain 132(2): 383-391 (2009).
11. Donix M, Burggren A, Suthana N, Siddarth P, Ekstrom AD, Krupa AK, et al. Family history of Alzheimer’s disease and hippocampal structure in healthy people. Am J Psych 167(11): 1399-1406 (2010).
12. Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, Alexander AL, et al. White matter is altered with parental family history of Alzheimer’s disease. Alzheimers Dement 6(5): 394-403 (2010).
13. Gold BT, Powell DK, Andersen AH, Smith CD. Alterations in multiple measures of white matter integrity in normal women at high risk for Alzheimer’s disease. NeuroImage 52(4): 1487-1494 (2010).
14. Smith CD, Chebrolu H, Andersen AH, Powell DA, Lovell MA, Xiong S, et al. White matter diffusion alterations in normal women at risk of Alzheimer’s disease. Neurobiol Aging 31(7): 1122-1131 (2010).
15. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, et al. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer’s. Proc Natl Acad Sci USA 107(13): 5949-5954 (2010).
16. Woods AG, Sokolowska I, Taurines R, Gerlach M, Dudley E, Thome J, et al. Potential biomarkers in psychiatry: focus on the cholesterol system. J Cell Mol Med 16(6): 1184-1195 (2012).
17. Kotze MJ, Lückhoff HK, Brand T, Pretorius J, van Rensburg SJ. Apolipoprotein ε-4 as a genetic determinant of Alzheimer’s disease heterogeneity. Degener Neurol Neuromuscul 5: 9-18 (2015).
18. Conejero-Goldberg C, Gomar JJ, Bobes-Bascaran T, Hyde TM, Kleinman JE, Herman MM, et al. APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms. Mol Psychiatry 1-8 (2014).
19. Farr SA, Yamada KA, Butterfield DA, Abdul HM, Xu L, Miller NE, et al. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 149(5): 2628-2636 (2008).
20. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, et al. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32(1): 169-174 (2009).
21. Kotze MJ, van Rensburg SJ. Pathology supported genetic testing and treatment of cardiovascular disease in middle age for prevention of Alzheimer's disease. Metab Brain Dis 27(3): 255-266 (2012).
22. Lopez-Miranda J, Ordovas JM, Mata P, Lichtenstein AH, Clevidence B, Judd JT, et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J Lipid Res 35(11): 1965-1975 (1994).
23. Zambón D, Quintana M, Mata P, Alonso R, Benavent J, Cruz- Sánchez F, et al. Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 123(3): 267-274 (2010).
24. Kotze MJ, Langenhoven E, Theart L, Marx MP, Oosthuizen CJ. Report on a molecular diagnostic service for familial hypercholesterolemia in Afrikaners. Genet Counseling 5: 15-21 (1994).
25. Kotze MJ, van Velden DP, Botha K, Badenhorst CH, Avenant H, van Rensburg SJ, et al. Pathology-supported genetic testing directed at shared disease pathways for optimized health in later life. Personalized Medicine 10(5): 497-507 (2013).
26. Rahman B, Meiser B, Sachdev P, Barlow-Stewart K, Otlowski M, Zilliacus E, et al. To know or not to know: an update of the literature on the psychological and behavioral impact of genetic testing for Alzheimer disease risk. Genet Test Mol Biomarkers 16(8): 935-942 (2012).
27. Hudson JM, Pollux PM, Mistry B, Hobson S. Beliefs about Alzheimer's disease in Britain Aging Ment Health 16(7): 828-835 (2012).
28. Kotze MJ, de Villiers WJS, Steyn K, Kriek JA, Marais AD, Langenhoven E, et al. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 13: 1460-1468 (1993).
29. Obisesan TO, Gillum RF, Johnson S, Umar N, Williams D, Bond V, et al. Neuroprotection and neurodegeneration in Alzheimer's disease: role of cardiovascular disease risk factors, implications for dementia rates, and prevention with aerobic exercise in African Americans. Int J Alzheimers Dis 2012: 568382 (2012).
30. Kivipelto M, Rovio S, Ngandu T, Kåreholt I, Eskelinen M, Winblad B, et al. Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. J Cell Mol Med 12(6): 2762-2771 (2008).
31. Scarmeas N, Luchsinger JA, Brickman AM, Cosentino S, Schupf N, Xin-Tang M, et al. Physical activity and Alzheimer disease course. Am J Geriatr Psychiatry 19(5): 471-481 (2011).
32. Maloney B, Ge YW, Petersen RC, Hardy J, Rogers JT, Pérez-Tur J, et al. Functional characterization of three single-nucleotide polymorphisms present in the human APOE promoter sequence: Differential effects in neuronal cells and on DNA-protein interactions. Am J Med Genet B Neuropsychiatr Genet 153B(1): 185-201 (2010).
33. Bernstein MS, Costanza MC, James RW, Morris MA, Cambien F, Raoux S, et al. Physical activity may modulate effects of ApoE genotype on lipid profile. Arterioscler Thromb Vasc Biol 22(1): 133-140 (2002).
34. Kotze MJ, Schörn D, Coetzer P. The impact of genetic testing on life insurance. J Genomics Afr Soc 1: 1-11 (2004).
35. Taylor DH Jr, Cook-Deegan RM, Hiraki S, Roberts JS, Blazer DG, Green RC. Genetic testing for Alzheimer's and long-term care insurance. Health Aff (Millwood) 29(1): 102-108 (2010).
36. Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. Willingness to pay for genetic testing for Alzheimer's disease: a measure of personal utility. Genet Test Mol Biomarkers 15(12): 871-875 (2011).
37. Christensen KD, Roberts JS, Uhlmann WR, Green RC. Changes to perceptions of the pros and cons of genetic susceptibility testing after APOE genotyping for Alzheimer disease risk. Genet Med 13(5): 409-414 (2011).
38. Sawyer K, Sachs-Ericsson N, Preacher KJ, Blazer DG. Racial differences in the influence of the APOE epsilon 4 allele on cognitive decline in a sample of community-dwelling older adults. Gerontology 55(1): 32-40 (2009).
39. Katz MJ, Lipton RB, Hall CB, Zimmerman ME, Sanders AE, Verghese J, et al. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites: a report from the Einstein Aging Study. Alzheimer Dis Assoc Disord 26(4): 335-342 (2012).
40. Loubser O, Marais AD, Kotze MJ, Godenir N, Thiart R, Scholtz CL, et al. Founder mutations in the LDL receptor gene contribute significantly to the familial hypercholesterolemia phenotype in the indigenous South African population of mixed ancestry. Clin Genet 55(5): 340-345 (1999).
41. Tishkoff SA, Reed FA, Friedlaender R, Ehret C, Ranciaro A, Froment A, et al. The genetic structure and history of Africans and African Americans. Science 324(5930): 1035-1044 (2009).
42. Sun X, Nicholas J, Walker A, Wagner MT, Bachman D. APOE genotype in the diagnosis of Alzheimer's disease in patients with cognitive impairment. Am J Alzheimers Dis Other Demen 27(5): 315-320 (2012).
43. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimers Res Ther 4(1): 1 (2012).
44. Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. J Alzheimers Dis 32(3): 531-40 (2012).
45. Donnelly LA, Palmer CN, Whitley AL, Lang CC, Doney AS, Morris AD, et al. Apolipoprotein E genotypes are associated with lipidlowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 18(4): 279-287 (2008).
46. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer’s disease: a major gene with semi-dominant inheritance. Mol Psychiatry 16(9): 903-907 (2011).